Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
      • Doodle Gallery
      • Circulation Cover Doodle
    • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • → Articles Bridging Discplines
    • Cardiovascular Case Series
    • Circulation Supplements
    • ECG Challenge
    • Hospitals of History
      • Hospital Santa Maria del Popolo, Naples, Italy
      • Minneapolis City Hospital
      • Pitié-Salpêtrière Hospital
      • Tufts Medical Center
      • Uppsala University Hospital
      • Vassar Brothers Medical Center (Poughkeepsie, NY)
      • Wroclaw Medical University
    • On My Mind
    • Podcast Archive
      • → Circulation on the Run, FIT Edition
    • → Subscribe to Circulation on the Run
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
    • Scientific Sessions 2017
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Cardiovascular Genetics
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
    • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • → Articles Bridging Discplines
    • Cardiovascular Case Series
    • Circulation Supplements
    • ECG Challenge
    • Hospitals of History
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
    • Scientific Sessions 2017
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Cardiovascular Genetics
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Core 2. Epidemiology and Prevention of CV Disease: Physiology, Pharmacology and LifestyleSession Title: Population-Based Interventions and Health Policy

Abstract 16758: Eligibility for Lipid Lowering Therapy, Coronary Artery Calcification, and CHD Events - National Implications for the Appropriate Use of Preventive Pharmacotherapy: Multi-Ethnic Study of Atherosclerosis (MESA)

Khurram Nasir, Michael J Blaha, Matthew J Budoff, Ron Blankstien, Arthur S Agatston, Christopher T Sibley, Leslee J Shaw, Roger S Blumenthal, Harlan Krumholz
Circulation. 2012;126:A16758
Khurram Nasir
Prevention and Wellness, Baptist Health South Florida, Coral Gables, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J Blaha
Cardiology, Ciccarone Preventive Cardiology Cntr, Johns Hopkins Univ, Sch of Medicine, Baltimore, MD, Baltimore, MD,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J Budoff
Cardiology, Los Angeles Biomedical Rsch Institute, Torrance, CA,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ron Blankstien
Cardiology, Brigham and Women's Hosp, Harvard Sch of Medicine, Boston, MA,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur S Agatston
Prevention and Wellness, Baptist Health South Florida, Coral Gables, FL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher T Sibley
Clinical research Unit, National Institute of Health, Bethesda, MD,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslee J Shaw
Emory Clinical Cardiovascular Rsch Institute, Emory Univ Sch of Medicine, Atlanta, GA,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger S Blumenthal
Cardiology, Ciccarone Preventive Cardiology Cntr, Johns Hopkins Univ, Sch of Medicine, Baltimore, MD, Baltimore, MD,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harlan Krumholz
Yale-New Haven Hosp Cntr for Outcomes Rsch and Evaluation, Yale Univ, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics

Jump to

  • Article
  • Info & Metrics
  • eLetters
Loading

Abstract

Background: In last 2 decades, the threshold of individuals meeting eligibility criteria (EC) for life long lipid lowering medication (LLM) has progressively decreased. As per CDC, 1 in 4 people 45 and older are using statins. We sought to determine whether coronary artery calcium (CAC) testing may identify subgroups among those meeting/not meeting EC for LLM who are expected to derive the most, and the least, benefit from the prescribed pharmacotherapy.

Methods: MESA is a longitudinal, population-based study of 6,814 men and women aged 45-84 without clinical cardiovascular disease at enrollment. A total of 1100 (16%) participants on LLM at baseline were excluded from analysis. We also excluded 88 individuals (1.3%) with absent LDL levels, as well as 1 participant with no information on CHD event.

Results: The final study population consisted of 5,603 individuals (62±10 years, 47% males) followed for a median 5.8 years. Based on the NCEP guidelines, 1,368 (24%) met EC for LLM. Of those, 468 (34%) with CAC=0 had 2.7 CHD events/1000 person-years. There were 469 (34%) with CAC>100 and they had 28.9 CHD events/1000 person-years, with 2/3 (64%) of events occurring in this group. The number needed to screen(NNS) to identify 1 individual with CAC=0 was 3 among those meeting EC for LLM. On the other hand 17% of individuals not meeting EC for LLM had CAC>100 with CHD rate of 17.2/1000 person-years; 62% of all events occurred in this group and NNS to identify these high risk individuals was 6.

Conclusion: Within MESA, 1/3 of patients meeting EC for LLM had CAC=0 & these individuals experienced a very low event rate. Conversely those with high CAC and not meeting EC for LLM had very high event rates. Our study findings suggest that CAC testing helps in identification of heterogeneity of risk among those considered eligible and not eligible for LLM according to the current guidelines.

Embedded Image

  • Outcomes
  • Statins
  • Health services research
  • Calcification
  • Guidelines
  • © 2012 by American Heart Association, Inc.
Back to top
Previous Article

This Issue

Circulation
20 November 2012, Volume 126, Issue Suppl 21
  • Table of Contents
Previous Article

Jump to

  • Article
  • Info & Metrics

Article Tools

  • Citation Tools
    Abstract 16758: Eligibility for Lipid Lowering Therapy, Coronary Artery Calcification, and CHD Events - National Implications for the Appropriate Use of Preventive Pharmacotherapy: Multi-Ethnic Study of Atherosclerosis (MESA)
    Khurram Nasir, Michael J Blaha, Matthew J Budoff, Ron Blankstien, Arthur S Agatston, Christopher T Sibley, Leslee J Shaw, Roger S Blumenthal and Harlan Krumholz
    Circulation. 2012;126:A16758, originally published January 6, 2016

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Abstract 16758: Eligibility for Lipid Lowering Therapy, Coronary Artery Calcification, and CHD Events - National Implications for the Appropriate Use of Preventive Pharmacotherapy: Multi-Ethnic Study of Atherosclerosis (MESA)
    (Your Name) has sent you a message from Circulation
    (Your Name) thought you would like to see the Circulation web site.
  • Share on Social Media
    Abstract 16758: Eligibility for Lipid Lowering Therapy, Coronary Artery Calcification, and CHD Events - National Implications for the Appropriate Use of Preventive Pharmacotherapy: Multi-Ethnic Study of Atherosclerosis (MESA)
    Khurram Nasir, Michael J Blaha, Matthew J Budoff, Ron Blankstien, Arthur S Agatston, Christopher T Sibley, Leslee J Shaw, Roger S Blumenthal and Harlan Krumholz
    Circulation. 2012;126:A16758, originally published January 6, 2016
    Permalink:
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Circulation

  • About Circulation
  • Instructions for Authors
  • Circulation CME
  • Statements and Guidelines
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451
email: circ@circulationjournal.org
 

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2017 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured